Blum H E
Departement für Innere Medizin, Universitätsspital Zürich.
Schweiz Rundsch Med Prax. 1993 Apr 27;82(17):501-5.
Viral infections are major causes of chronic liver diseases. The etiologic agents are hepatitis B virus (HBV), the HBV-associated hepatitis delta virus (HDV) and hepatitis C (HCV). In general, these viral infections can be specifically identified by serological tests and molecular techniques. The identification of the causative agents is clinically relevant both for epidemiologic-preventive and therapeutic considerations. The therapy of choice for chronic viral hepatitis B or C is interferon-alfa (10 mill units 3x per week for about 6 months). The long-term response rate is 30 to 40% for chronic hepatitis B and 20 to 30% for chronic hepatitis C. The results for chronic hepatitis D are controversial at present. Based on these results, therapeutic strategies have to be modified and improved further. Apart from therapeutic considerations, measures to prevent viral hepatitides should be carefully implemented (HBV vaccination of individuals at risk, reduction of blood transfusions, general hygienic measures), in order to reduce the morbidity and mortality from acute and chronic hepatitis, including liver cirrhosis and hepatocellular carcinoma.
病毒感染是慢性肝病的主要病因。病原体为乙型肝炎病毒(HBV)、与HBV相关的丁型肝炎病毒(HDV)和丙型肝炎病毒(HCV)。一般来说,这些病毒感染可通过血清学检测和分子技术进行特异性鉴定。病原体的鉴定对于流行病学预防和治疗考量在临床上都具有相关性。慢性乙型或丙型病毒性肝炎的首选治疗方法是α干扰素(每周3次,每次10百万单位,持续约6个月)。慢性乙型肝炎的长期缓解率为30%至40%,慢性丙型肝炎为20%至30%。目前慢性丁型肝炎的治疗结果存在争议。基于这些结果,治疗策略必须进一步修改和完善。除了治疗考量外,还应认真实施预防病毒性肝炎的措施(对高危个体进行HBV疫苗接种、减少输血、采取一般卫生措施),以降低急性和慢性肝炎(包括肝硬化和肝细胞癌)的发病率和死亡率。